相关实验视频

Updated: Jul 13, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

癌症/Testis抗原作为基于RNA的抗癌疗法的点

Kyeonghee Shim¹, Hyein Jo¹, Dooil Jeoung¹

¹Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 24341, Republic of Korea.

International journal of molecular sciences

|October 14, 2023

概括

使者RNA (mRNA) 疗法在治疗疾病方面表现有前途. 本综述探讨了使用外体和脂质纳米颗粒 (LNP) 的mRNA传递,重点关注用于免疫治疗的癌症/丸抗原 (CTA).

科学领域:

生物技术是生物技术.
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

基于RNA的疗法,特别是信使RNA (mRNA),为蛋白质生产提供了一个多功能平台,使新的治疗策略成为可能.
有效的输送系统对于RNA疗法的临床应用至关重要.
癌症/丸抗原 (CTA) 是癌症免疫治疗的理想点,因为它们在正常组织中的表达受限,在瘤中的表达广泛.

研究的目的:

审查外体和脂质纳米粒子 (LNP) 作为mRNA的输送载体的潜力.
概述CTAs在生物过程中的作用以及目前对编码CTAs的mRNA的研究.
突出使用编码CTA的mRNA-LNP用于癌症治疗的临床研究.

主要方法:

关于mRNA传递系统 (外体和LNP) 的研究的文献综述.
对癌症/丸抗原 (CTA) 和它们编码的mRNA的研究分析.
对针对CTA的mRNA-LNP疗法的临床试验数据的摘要.

主要成果:

外体和LNP是提供mRNA治疗的可行和有前途的载体.
编码CTA的mRNA在癌症的发展和进展中发挥了重要作用.
临床研究表明,使用编码CTAs的mRNA-LNP治疗癌症患者的结果很有希望.

结论:

对于开发有效的癌症免疫疗法,mRNA-LNP技术具有巨大的潜力.
用基于mRNA的疫苗向CTA代表了癌症治疗的一个有希望的途径.
需要进一步的研究和临床试验来优化mRNA输送和基于CTA的癌症疗法.

关键词:

配送RNA配送RNA的时间它们是RNA疫苗.癌症 / 丸抗原临床试验是指临床试验中的临床试验.脂质纳米颗粒的使用方法与瘤相关的抗原.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...